Medicamentos de actualidad = Drugs of today

• 

  Año 2019, Vol. 55, Número 4

  • MONOGRAPHS

    • Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer

      Tatsuya Nagano, Motoko Tachihara, Yoshihiro Nishimura

      • Resumen

      págs. 231-236

      

    • Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.

      Fabio Barra, Carolina Scala, Simone Ferrero

      • Resumen

      págs. 237-246

      

    • Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma

      April A.N. Rose

      • Resumen

      págs. 247-264

      

    • Fremanezumab for the prevention of chronic and episodic migraine

      Luana Lionetto, Fabiola Cipolla, Martina Guglielmetti, Paolo Martelletti

      • Resumen

      págs. 265-276

      

  • REVIEW

    • Unintended consequences of the new ACC/AHA blood pressure treatment guidelines

      Steven G. Chrysant, George S. Chrysant

      • Resumen

      págs. 277-285

      

  • MEETING REPORT

    • World Pharma Pricing and Market Access Congress – 11th Terrapinn Congress (March 19-20, 2019 – Amsterdam, the Netherlands).

      Jessica Barkan

      • Resumen

      págs. 287-290

      

  • NEW PRODUCT INTROS

    • New product intros [esketamine hydrochloride (new indication, new formulation); intravenous immunoglobulin, human; tagraxofusp-erzs; toripalimab].

      págs. 291-292